

Summary table

Sample size

478 events in the original dataset, one of them is excluded due to lack of outcome (outcome = NA). -> n = 477

After removing 16 repeat visits (itt = 0), there are 461 patients in total, -> n = 461

There are 421 patients after removing 40 non-epileptic (final_dx = "Non-epileptic spell") -> n = 421

Tables 1 include 421 patients by treatment

	data (N = 421)	A (N = 159)	B (N = 131)	C (N = 131)
Age				
mean (sd)	28.19 ± 26.22	28.80 ± 26.86	27.28 ± 25.45	28.35 ± 26.38
Range	1-94	1-94	1-84	1-85
NA	0(0%)	0(0%)	0(0%)	0(0%)
Age Group				
0-17y	217 (51.54%)	81 (50.94%)	70 (53.44%)	66 (50.38%)
18y - 60 y	135 (32.07%)	54 (33.96%)	39 (29.77%)	42 (32.06%)
>60 y	69 (16.39%)	24 (15.09%)	22 (16.79%)	23 (17.56%)
Gender				
Female	176 (41.81%)	69 (43.40%)	52 (39.69%)	55 (41.98%)
Male	245 (58.19%)	90 (56.60%)	79 (60.31%)	76 (58.02%)
Race				
Black	182 (43.23%)	70 (44.03%)	51 (38.93%)	61 (46.56%)
White	179 (42.52%)	68 (42.77%)	59 (45.04%)	52 (39.69%)
Asian	17 (4.04%)	7 (4.40%)	5 (3.82%)	5 (3.82%)
Other	11 (2.61%)	5 (3.14%)	3 (2.29%)	3 (2.29%)
Unknown	32 (7.60%)	9 (5.66%)	13 (9.92%)	10 (7.63%)
Ethnicity				

	data (N = 421)	A (N = 159)	B (N = 131)	C (N = 131)
Hispanic	71 (16.86%)	28 (17.61%)	19 (14.50%)	24 (18.32%)
Non-Hispanic	350 (83.14%)	131 (82.39%)	112 (85.50%)	107 (81.68%)
Home antiepileptic medications				
0	107 (25.42%)	40 (25.16%)	29 (22.14%)	38 (29.01%)
1	125 (29.69%)	47 (29.56%)	42 (32.06%)	36 (27.48%)
2	97 (23.04%)	37 (23.27%)	34 (25.95%)	26 (19.85%)
3	48 (11.40%)	17 (10.69%)	17 (12.98%)	14 (10.69%)
4	24 (5.70%)	9 (5.66%)	4 (3.05%)	11 (8.40%)
5	14 (3.33%)	6 (3.77%)	4 (3.05%)	4 (3.05%)
6	6 (1.43%)	3 (1.89%)	1 (0.76%)	2 (1.53%)
History of epilepsy				
Yes	305 (72.79%)	112 (70.89%)	98 (75.38%)	95 (72.52%)
No	114 (27.21%)	46 (29.11%)	32 (24.62%)	36 (27.48%)
NA	2(0.48%)	1(0.63%)	1(0.76%)	0(0%)
Median duration of seizure				
mean (sd)	77.47 ± 60.07	73.72 ± 46.88	80.96 ± 72.33	78.57 ± 61.25
Range	6-620	6-305	10-620	10-377
NA	29(6.89%)	10(6.29%)	10(7.63%)	9(6.87%)
Benzodiazepines given before ED arrival				
Yes	192 (55.49%)	78 (59.54%)	61 (57.01%)	53 (49.07%)
No	154 (44.51%)	53 (40.46%)	46 (42.99%)	55 (50.93%)
NA	75(17.81%)	28(17.61%)	24(18.32%)	23(17.56%)
Number of benzo doses				
mean (sd)	2.48 ± 0.94	2.56 ± 0.97	2.47 ± 0.89	2.39 ± 0.97
Range	1-7	1-7	1-5	1-6
NA	0(0%)	0(0%)	0(0%)	0(0%)

	data (N = 421)	A (N = 159)	B (N = 131)	C (N = 131)
Interval between 1st dose of benzo and administration of the study drug				
mean (sd)	49.59 ± 63.11	49.99 ± 45.72	51.98 ± 80.04	46.70 ± 62.51
Range	5-857	6-335	7-857	5-557
NA	0(0%)	0(0%)	0(0%)	0(0%)

Table 2 Seizure types

	Success.A (N = 93)	Success.B (N = 71)	Success.C (N = 77)	Failure.A (N = 66)	Failure.B (N = 60)	Failure.C (N = 54)
Seizure Type						
Stroke	3 (3.23%)	4 (5.63%)	1 (1.30%)	3 (4.55%)	4 (6.67%)	2 (3.70%)
Electrolyte anomalies	2 (2.15%)	0 (0.00%)	0 (0.00%)	1 (1.52%)	2 (3.33%)	1 (1.85%)
CNS Tumors/CNS infection	1 (1.08%)	3 (4.23%)	0 (0.00%)	4 (6.06%)	2 (3.33%)	5 (9.26%)
Unprovoked	32 (34.41%)	22 (30.99%)	27 (35.06%)	23 (34.85%)	28 (46.67%)	12 (22.22%)
Anti-epileptic drug withdrawal/non compliance	14 (15.05%)	10 (14.08%)	13 (16.88%)	10 (15.15%)	5 (8.33%)	3 (5.56%)
Febrile illness	22 (23.66%)	16 (22.54%)	20 (25.97%)	9 (13.64%)	8 (13.33%)	15 (27.78%)
Insufficient information to determine/idiopathic/cryptogenic	0 (0.00%)	2 (2.82%)	4 (5.19%)	7 (10.61%)	1 (1.67%)	4 (7.41%)
Toxic (alcohol / drug withdrawal-not AEDs, poisoning, etc.)	6 (6.45%)	3 (4.23%)	3 (3.90%)	5 (7.58%)	3 (5.00%)	5 (9.26%)
Other	13 (13.98%)	11 (15.49%)	9 (11.69%)	4 (6.06%)	7 (11.67%)	7 (12.96%)